Capricor Therapeutics Inc

CAPRNASDAQ · USD
9.06USD0.00 (-3.83%)
1210

Capricor Therapeutics Inc (CAPR) Options Open Interest

CAPR options open interest is 216,647 contracts. The 2-week average daily volume is 12,063 contracts across the chain.

Read more

Monitoring CAPR open interest helps you see where real money is positioned on Capricor Therapeutics Inc's options and which strikes are attracting the most commitment from traders. Capricor Therapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CAPR options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CAPR options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Capricor Therapeutics Inc to settle.

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19.

It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CAPR open interest is concentrated. Our scanner maps Capricor Therapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Capricor Therapeutics Inc's options open interest as the signal it is, not as an afterthought.

2026-09-25
Calls
10.000.500.50134%+0.4185309
12.000.350.35200%+0.2468154
8.500.601.801.20122%+0.7498153
9.000.401.400.90125%+0.6357112
8.000.803.101.95218%+0.75099
Puts
6.000.500.50390%-0.1397200
8.000.200.20138%-0.1784157
7.004.404.401,000%-0.17603
9.000.250.850.55140%-0.37061
12.001.954.903.43305%-0.62711

As of September 18, 2026

Follow the money

Track CAPR open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.

Start your 14-day free trial